Newron Pharmaceuticals S.p.A. Stock Xetra
Stocks
NP5
IT0004147952
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.75 EUR | -1.92% |
|
+0.39% | -51.61% |
| 07-03 | Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment | MT |
| 05-05 | Edison Is Not Overly Concerned About a Trial Suspension |  |
| Market Cap | 266M 303M 247M 227M 426M 29.14B 433M 2.94B 1.15B 14.33B 1.14B 1.11B 49.54B | P/E 2026 * |
-9.41x | P/E 2027 * | 34.5x |
|---|---|---|---|---|---|
| Enterprise Value | 304M 347M 283M 260M 488M 33.38B 496M 3.36B 1.31B 16.41B 1.3B 1.27B 56.75B | EV / Sales 2026 * |
28.1x | EV / Sales 2027 * | 6.26x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | -1.92% | ||
| 1 week | +0.39% | ||
| Current month | -9.25% | ||
| 1 month | -6.59% | ||
| 3 months | -26.09% | ||
| 6 months | -45.04% | ||
| Current year | -51.61% |
| 1 week | 12.2 |  | 13.25 |
| 1 month | 12.2 | | 14.2 |
| Current year | 12.2 | | 34.65 |
| 1 year | 7.16 | | 34.65 |
| 3 years | 4.26 | | 34.65 |
| 5 years | 1.13 | | 34.65 |
| 10 years | 1.13 | | 34.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
Gillian Dines
BRD | Director/Board Member | - | 01/04/2023 |
Margarita Chavez
BRD | Director/Board Member | - | 17/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.92% | +0.39% | - | - | 303M | |
| +1.07% | -3.49% | -3.35% | +10.44% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +634.87% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +65.64% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.16% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +40.92% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.36% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.03% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -33.61% | 12.7B | |
| Average | +0.01% | +0.83% | +54.56% | +106.44% | 27.25B | |
| Weighted average by Cap. | +0.48% | +0.91% | +74.42% | +136.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.84M 12.35M 10.08M 9.25M 17.39M 1.19B 17.65M 120M 46.78M 585M 46.35M 45.35M 2.02B | 44.83M 51.04M 41.69M 38.26M 71.88M 4.92B 72.99M 495M 193M 2.42B 192M 187M 8.36B |
| Net income | -31.17M -35.49M -28.99M -26.6M -49.99M -3.42B -50.76M -344M -135M -1.68B -133M -130M -5.81B | 5.02M 5.72M 4.67M 4.29M 8.05M 551M 8.18M 55.47M 21.67M 271M 21.47M 21.01M 936M |
| Net Debt | 38.68M 44.04M 35.98M 33.01M 62.03M 4.24B 62.98M 427M 167M 2.09B 165M 162M 7.21B | 14.72M 16.76M 13.69M 12.56M 23.6M 1.61B 23.96M 163M 63.5M 793M 62.9M 61.55M 2.74B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | €12.75 | -1.92% | 6,695 |
| 23/07/26 | €13.00 | -0.38% | 1,590 |
| 22/07/26 | €13.05 | +1.16% | 2,798 |
| 21/07/26 | €12.90 | +4.45% | 4,072 |
| 20/07/26 | €12.35 | -2.76% | 197 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NWRN Stock
- NP5 Stock
Select your edition
All financial news and data tailored to specific country editions
